California Public Employees Retirement System Sells 32,938 Shares of Insulet Corporation $PODD

California Public Employees Retirement System trimmed its stake in shares of Insulet Corporation (NASDAQ:PODD) by 26.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 90,200 shares of the medical instruments supplier’s stock after selling 32,938 shares during the quarter. California Public Employees Retirement System’s holdings in Insulet were worth $18,928,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. NewEdge Advisors LLC increased its holdings in shares of Insulet by 44.8% during the first quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock worth $54,000 after buying an additional 64 shares in the last quarter. Cresset Asset Management LLC lifted its stake in shares of Insulet by 7.3% in the 2nd quarter. Cresset Asset Management LLC now owns 2,587 shares of the medical instruments supplier’s stock valued at $813,000 after acquiring an additional 177 shares during the last quarter. Cerity Partners LLC boosted its holdings in shares of Insulet by 68.7% during the 2nd quarter. Cerity Partners LLC now owns 17,262 shares of the medical instruments supplier’s stock valued at $5,423,000 after acquiring an additional 7,030 shares in the last quarter. Sei Investments Co. boosted its holdings in shares of Insulet by 27.4% during the 2nd quarter. Sei Investments Co. now owns 137,643 shares of the medical instruments supplier’s stock valued at $43,245,000 after acquiring an additional 29,584 shares in the last quarter. Finally, Treasurer of the State of North Carolina grew its position in Insulet by 2.5% during the 2nd quarter. Treasurer of the State of North Carolina now owns 32,752 shares of the medical instruments supplier’s stock worth $10,290,000 after acquiring an additional 791 shares during the last quarter.

Wall Street Analyst Weigh In

PODD has been the subject of a number of recent research reports. Sanford C. Bernstein lowered their target price on Insulet from $330.00 to $200.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. William Blair began coverage on Insulet in a research note on Wednesday, May 20th. They set an “outperform” rating on the stock. Barclays reduced their price target on Insulet from $286.00 to $198.00 and set an “underweight” rating on the stock in a report on Thursday, May 7th. JPMorgan Chase & Co. lowered their price objective on Insulet from $340.00 to $275.00 and set an “overweight” rating for the company in a research note on Thursday, May 7th. Finally, Canaccord Genuity Group dropped their price objective on shares of Insulet from $435.00 to $249.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Twenty-two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $235.25.

Insulet News Summary

Here are the key news stories impacting Insulet this week:

• Negative Sentiment: Multiple law firms announced or promoted class action lawsuits against Insulet, with investors urged to contact counsel ahead of the August 31 lead-plaintiff deadline. These actions add legal overhang and keep attention on prior disclosures.PODD Investors Have Opportunity to Lead Insulet Corporation Securities Fraud Lawsuit
• Negative Sentiment: The lawsuits allege Insulet misled investors about manufacturing controls at its Acton facility, including claims that defective controls may have produced millions of flawed Omnipod pods and created insulin under-delivery risks.PODD Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Insulet Corporation Securities Lawsuit – Contact Levi & Korsinsky
• Neutral Sentiment: The company’s last reported earnings were strong, with revenue and EPS beating Wall Street expectations and year-over-year revenue growth of 33.9%, which helps offset some of the legal concerns but is not the main driver of today’s move.

Insulet Stock Performance

NASDAQ PODD opened at $158.38 on Friday. The company has a market capitalization of $10.97 billion, a price-to-earnings ratio of 36.83, a PEG ratio of 1.11 and a beta of 1.11. Insulet Corporation has a twelve month low of $138.79 and a twelve month high of $354.88. The stock has a fifty day simple moving average of $153.77 and a 200 day simple moving average of $202.89. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71.

Insulet (NASDAQ:PODD) last announced its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, topping the consensus estimate of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm had revenue of $761.70 million for the quarter, compared to the consensus estimate of $729.89 million. During the same period in the previous year, the business earned $1.02 EPS. The business’s quarterly revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. Sell-side analysts expect that Insulet Corporation will post 6.45 EPS for the current year.

Insider Activity

In related news, Director Timothy C. Stonesifer acquired 2,790 shares of the stock in a transaction dated Wednesday, June 3rd. The stock was bought at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the transaction, the director directly owned 9,041 shares of the company’s stock, valued at $1,297,473.91. The trade was a 44.63% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.36% of the stock is owned by company insiders.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.